A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults

Jenny G. Low, Ruklanthi de Alwis, Shiwei Chen, Shirin Kalimuddin, Yan Shan Leong, Tania Ken Lin Mah, Natalene Yuen, Hwee Cheng Tan, Summer L Zhang, Jean X.Y. Sim, Yvonne F.Z. Chan, Ayesa Syenina, Jia Xin Yee, Eugenia Z. Ong, Rose Sekulovich, Brian B. Sullivan, Kelly Lindert, Sean B. Sullivan, Pad Chivukula, Steven G. Hughes, Eng Eong. Ooi
doi: https://doi.org/10.1101/2021.07.01.21259831

Data Availability

Data available upon request and with necessary approvals from the corresponding author.

Back to top
Posted July 02, 2021.
Download PDF
Data/Code
Email
A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
Jenny G. Low, Ruklanthi de Alwis, Shiwei Chen, Shirin Kalimuddin, Yan Shan Leong, Tania Ken Lin Mah, Natalene Yuen, Hwee Cheng Tan, Summer L Zhang, Jean X.Y. Sim, Yvonne F.Z. Chan, Ayesa Syenina, Jia Xin Yee, Eugenia Z. Ong, Rose Sekulovich, Brian B. Sullivan, Kelly Lindert, Sean B. Sullivan, Pad Chivukula, Steven G. Hughes, Eng Eong. Ooi
medRxiv 2021.07.01.21259831; doi: https://doi.org/10.1101/2021.07.01.21259831
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area